TRRI OTC
Alzex Neuropharma Inc.
1W: +0.0%
1M: +0.0%
3M: -66.7%
YTD: +100.0%
1Y: -99.4%
3Y: -99.7%
5Y: -99.6%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$163K
-604.4% ▼
Net Income
-$166K
-853.8% ▼
EPS (Diluted)
$-0.11
-853.4% ▼
EBITDA
-$163K
-163.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2010 | FY2012 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $4M | $0 | $0 | $0 | $0 |
| YoY Growth | -56.6% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $3M | $0 | $0 | $0 | $0 |
| Gross Profit | $382K | $0 | $0 | $0 | $0 |
| Gross Margin | 10.0% | — | — | — | — |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $269K | $31K | $3K | $23K | $163K |
| Operating Expenses | $269K | $31K | $3K | $23K | $163K |
| Operating Income | $113K | -$31K | -$3K | -$23K | -$163K |
| Operating Margin | 2.9% | — | — | — | — |
| Interest Expense | $33K | $8K | $0 | $0 | $2K |
| Income Before Tax | $80K | -$38K | -$3K | $22K | -$166K |
| Tax Expense | -$2 | $0 | $0 | $0 | $0 |
| Net Income | $80K | -$38K | -$3K | $22K | -$166K |
| Net Margin | 2.1% | — | — | — | — |
| EPS (Diluted) | $33.03 | $-0.03 | $-0.00 | $0.01 | $-0.11 |
| EBITDA | $183K | -$31K | $203K | $259K | -$163K |
| Shares Outstanding | 2416 | 1M | 2M | 2M | 2M |